ASSEMBLY BIOSCIENCES, INC. (ASMB) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ASMB currently has 16.9M outstanding shares. with moderate dilution risk from 3.83M authorized shares representing 22.7% potential dilution. The company has significantly diluted shareholders by 159.15% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 26, 2026 |
8-K filing: Assembly Biosciences, Inc. completed an underwritten registered offering of 3,358,602 shares of common stock, 415,000 pre-funded warrants, and an additional 566,040 shares via option exercise, resulting in approximately $107.4 million in net proceeds. |
17M | 3.8M |
| May 07, 2026 |
10-Q filing | 16.9M shares outstanding |
17M | 7.5M |
| Mar 19, 2026 |
S-3 filing: The company is filing an S-3 to offer shares of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units up to an aggregate offering price of $400,000,000. |
7.7M | 17M |
| Oct 14, 2025 |
S-3 filing: This prospectus relates to the offering and resale from time to time of up to 6,980,811 shares of common stock of Assembly Biosciences, Inc. by the selling stockholder identified in this prospectus. |
7.7M | 13M |
| Aug 06, 2025 |
10-Q filing | 7.7M shares outstanding |
7.7M | 6.1M |
| May 08, 2025 |
10-Q filing | 7.5M shares outstanding |
7.5M | 6.2M |
| Mar 20, 2025 |
S-3 filing: The company intends to offer, issue and sell, together or separately, from time to time in one or more offerings: shares of our common stock; shares of our preferred stock, which may be issued in one or more series; debt securities, which may be issued in one or more series and which may be senior debt securities or subordinated debt securities; warrants to purchase shares of our common stock, shares of our preferred stock or our debt securities; subscription rights to purchase shares of our common stock, shares of our preferred stock or our debt securities; and/ or units. |
6.4M | 7.4M |
| Mar 20, 2025 |
10-K filing | 7.5M shares outstanding |
7.5M | 6.2M |
| Dec 19, 2024 |
8-K filing: Gilead purchased 940,499 shares of Assembly Biosciences' common stock at $21.37 per share on December 19, 2024. ($20.1M proceeds) |
6.4M | 7.4M |
| Nov 07, 2024 |
10-Q filing | 6.4M shares outstanding |
6.4M | 7.4M |
| Aug 08, 2024 |
10-Q filing | 6.3M shares outstanding |
6.3M | 7.4M |
| May 08, 2024 |
10-Q filing | 5.5M shares outstanding |
5.5M | 8.3M |
| Mar 28, 2024 |
10-K filing | 5.5M shares outstanding |
5.5M | 8.3M |
| Feb 09, 2024 |
Stock Split
8-K filing: Stock split 1-for-12 | Outstanding: 65,709,112 → 5 |
5 | 14M |
| Nov 08, 2023 |
10-Q filing | 65.7M shares outstanding |
66M | 99M |
| Aug 09, 2023 |
10-Q filing | 52.3M shares outstanding |
52M | 110M |
| May 04, 2023 |
10-Q filing | 51.0M shares outstanding |
51M | 110M |
| Mar 22, 2023 |
S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, debt securities, warrants, subscription rights, and units up to an aggregate amount of $150,000,000. |
48M | 120M |
| Mar 22, 2023 |
10-K filing | 48.4M shares outstanding |
48M | 120M |
| Nov 08, 2022 |
10-Q filing | 48.4M shares outstanding |
48M | 0 |
| Aug 09, 2022 |
10-Q filing | 48.3M shares outstanding |
48M | 0 |
| May 12, 2022 |
10-Q filing | 48.2M shares outstanding |
48M | 0 |
| Mar 11, 2022 |
10-K filing | 48.1M shares outstanding |
48M | 0 |
| Nov 04, 2021 |
10-Q filing | 47.9M shares outstanding |
48M | 0 |
| Aug 05, 2021 |
10-Q filing | 42.9M shares outstanding |
43M | 0 |
| May 06, 2021 |
10-Q filing | 40.2M shares outstanding |
40M | 0 |
| Feb 25, 2021 |
10-K filing | 38.2M shares outstanding |
38M | 1.8M |
| Nov 05, 2020 |
10-Q filing | 33.0M shares outstanding |
33M | 7M |
| Aug 28, 2020 |
S-3 filing: The company may from time to time issue, in one or more series or classes, up to $300,000,000 of our common stock, preferred stock, debt securities, warrants and/or units. |
35M | 4.8M |
| Aug 05, 2020 |
10-Q filing | 35.3M shares outstanding |
35M | 0 |
| May 08, 2020 |
10-Q filing | 32.7M shares outstanding |
33M | 0 |
| Mar 04, 2020 |
10-K filing | 32.6M shares outstanding |
33M | 0 |